Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Safety Study of Intratumoural Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumour Malignancies

Next Previous
X
Search
Trial Profile

Phase I Safety Study of Intratumoural Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumour Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clostridium novyi-NT (Primary)
  • Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors BioMed Valley Discoveries

    • Most Recent Events

    • 12 Oct 2020 After the first patient was treated, the study was amended to exclude patients with clinical, functional, or radiographic evidence of bone involvement at the site of the target lesion for injection as per results published in the Clinical Cancer Research
    • 12 Oct 2020 Results published in the Clinical Cancer Research
    • 10 May 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top